NCT04180774View on ClinicalTrials.gov

Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
MelanomaKidney Cancer
Interventions
BIOLOGICAL

Tag-7 gene modified inactivated tumor cells

Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.

Trial Locations (1)

197758

N.N. Petrov Research Institute of Oncology Chemotherapy and Innovative Technologies Department, Saint Petersburg

All Listed Sponsors
collaborator

Institute of Gene Biology Russian Academy of Sciences

UNKNOWN

lead

N.N. Petrov National Medical Research Center of Oncology

OTHER

NCT04180774 - Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer | Biotech Hunter | Biotech Hunter